Bioelectronics Corp (BIEL)

[luke5516]

Hoping for a steady, sustained run like we had in April.

It sounds like we might be able to expect big things by the end of August (full FDA clearance and Dr. Scholl’s). I can be patient for that.

In the meantime, UK sales, including B. Braun’s use of patches in surgical kits should result in 2018 sales several times the size of 2017. That’s without any extra dealmaking, FDA action, or any other windfall.

In other words, we are on autopilot as sales numbers come in and get reported. The next quarter will include NHS reimbursement and the one after that will likely include the B. Braun increase.

By the time we have the first three quarters of increased earnings reported in November/early December, things will look much brighter based on numbers alone.

Add in FDA clearance, and Dr. Scholl’s and .18 isn’t that crazy for December. That’s a $3.6 bln market cap. If I’m big pharm, that’s pocket change for the cost of coopting a big disrupter to their bottom line.

And if I’m a betting person, BIEL’s a contender for this FDA pain relief contest. Wouldn’t that be a great PR! Maybe we’ll place or show (land in top 3) and be mentioned in a good article.

Multiple Y over Y Increased sales AND full FDA = Exacta.

Multiple Y over Y Increased sales AND full FDA AND Dr. Scholl’s = Trifecta.

Huge payout for a .0006-8 ticket (the cost basis for many of us).